Napigen
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Napigen - overview
Established
2016
Location
Wilmington, DE, US
Primary Industry
Biotechnology
About
Based in Delaware, US, and founded in 2016, Napigen operates as a biotechnology company. The company was founded by its CEO Hajime Sakai, Ganesh Kishore, Roger Wyse, and Jay Keasling. In July 2022, Napigen, Inc. raised USD 7.
9 million in seed funding co-led by the Grantham Foundation and RA Capital Management, MARSBIO, and the United Mitochondrial Disease Foundation. Napigen provides genome technology that focuses on changing cytoplasmic genomes, such as mitochondria and chloroplasts, enabling advancements in agribusiness, industrial biotechnology, and medical research. With the use of the company’s hybridization technology, crop plants that are now primarily non-hybrid, like wheat, can produce non-GM hybrid seeds, enabling a reduction in deforestation, which in turn helps to safeguard our environment and climate. The company plans to use the funds raised in July 2022 to develop hybrid seed technology in wheat and rice through gene editing of plant.
Current Investors
Thrive, Breakout Ventures, RA Capital Management
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Healthcare IT, Farm Support Services
Website
www.napigen.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.